

Expedited Procedure Under 37 C.F.C. §1.116
 Examining Group 1617
 Application No. 10/057,323
 Paper Dated: August 29, 2007
 Attorney Docket No. CV01489K (4686-045531)

RECEIVED
 CENTRAL FAX CENTER
 AUG 29 2007

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:


Listing of Claims

Claims 1-31. (Cancelled).

Claim 32 (Currently Amended): A composition comprising:

(a) at least one peroxisome proliferator-activated receptor activator;

(b) at least one sterol absorption inhibitor represented by Formula (I):



(I)

or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (I) or of the isomers thereof, or prodrugs of the compounds of Formula (I) or of the isomers, salts or solvates thereof,

wherein in Formula (I) above:

Ar¹ and Ar² are independently selected from the group consisting of aryl and R⁴-substituted aryl;

Ar³ is aryl or R⁵-substituted aryl;

X, Y and Z are independently selected from the group consisting of -CH₂-, -CH(lower alkyl)- and -C(dilower alkyl)-;

R and R² are independently selected from the group consisting of -OR⁶,

Expedited Procedure Under 37 C.F.C. §1.116
Examining Group 1617
 Application No. 10/057,323
 Paper Dated: August 29, 2007
 Attorney Docket No. CV01489K (4686-045531)

$-O(CO)R^6$, $-O(CO)OR^9$ and $-O(CO)NR^6R^7$;

R^1 and R^3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;

q is 0 or 1;

r is 0 or 1;

m , n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m , n , p , q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m , q and n is 1, 2, 3, 4 or 5;

R^4 is 1-5 substituents independently selected from the group consisting of lower alkyl, $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$, $-O(CH_2)_{1-5}OR^6$, $-O(CO)NR^6R^7$, $-NR^6R^7$, $-NR^6(CO)R^7$, $-NR^6(CO)OR^9$, $-NR^6(CO)NR^7R^8$, $-NR^6SO_2R^9$, $-COOR^6$, $-CONR^6R^7$, $-COR^6$, $-SO_2NR^6R^7$, $S(O)_{0-2}R^9$, $-O(CH_2)_{1-10}-COOR^6$, $-O(CH_2)_{1-10}CONR^6R^7$, $-(lower\ alkylene)COOR^6$, $-CH=CH-COOR^6$, $-CF_3$, $-CN$, $-NO_2$ and halogen;

R^5 is 1-5 substituents independently selected from the group consisting of $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$, $-O(CH_2)_{1-5}OR^6$, $-O(CO)NR^6R^7$, $-NR^6R^7$, $-NR^6(CO)R^7$, $-NR^6(CO)OR^9$, $-NR^6(CO)NR^7R^8$, $-NR^6SO_2R^9$, $-COOR^6$, $-CONR^6R^7$, $-COR^6$, $-SO_2NR^6R^7$, $S(O)_{0-2}R^9$, $-O(CH_2)_{1-10}-COOR^6$, $-O(CH_2)_{1-10}CONR^6R^7$, $-(lower\ alkylene)COOR^6$ and $-CH=CH-COOR^6$;

R^6 , R^7 and R^8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and

R^9 is lower alkyl, aryl or aryl-substituted lower alkyl; and

(c) ~~The composition according to claim 1, further comprising at least one cardiovascular agent selected from the group consisting of calcium channel blockers, adrenergic blockers, adrenergic stimulants, angiotensin converting enzyme (ACE) inhibitors, antihypertensive, angiotensin II receptor antagonists, anti-anginal agents, coronary vasodilators, diuretics and combinations thereof.~~

Claims 33-101. (Cancelled).

Expedited Procedure Under 37 C.F.C. §1.116
Examining Group 1617
Application No. 10/057,323
Paper Dated: August 29, 2007
Attorney Docket No. CV01489K (4686-045531)

Claim 102 (New): The composition according to claim 32, wherein the at least one peroxisome proliferator-activated receptor activator is a fibric acid derivative.


Claim 103 (New): The composition according to claim 102, wherein the fibric acid derivative is selected from the group consisting of fenofibrate, clofibrate, gemfibrozil, ciprofibrate, bezafibrate, clonofibrate, binifibrate, lifibrol and mixtures thereof.

Claim 104 (New): The composition according to claim 103, wherein the fibric acid derivative comprises fenofibrate.

Claim 105 (New): The composition according to claim 103, wherein the fibric acid derivative comprises gemfibrozil.

Claim 106 (New): The composition according to claim 32, wherein the at least one peroxisome proliferator-activated receptor activator is administered to a mammal in an amount ranging from about 50 to about 3000 milligrams of peroxisome proliferator-activated receptor activator per day.

Claim 107 (New): The composition according to claim 32, wherein the sterol absorption inhibitor is represented by Formula (II) below:



Expedited Procedure Under 37 C.F.C. §1.116
Examining Group 1617
Application No. 10/057,323
Paper Dated: August 29, 2007
Attorney Docket No. CV01489K (4686-045531)

or pharmaceutically acceptable salt or solvate thereof, or prodrug of the compound of Formula (II) or of the salt or solvate thereof.

Claim 108 (New): The composition according to claim 107, wherein the fibric acid derivative comprises fenofibrate.

Claim 109 (New): The composition according to claim 107, wherein the fibric acid derivative comprises gemfibrozil.

Claim 110 (New): The composition according to claim 32, wherein the at least one sterol absorption inhibitor is administered to a mammal in an amount ranging from about 0.1 to about 1000 milligrams of sterol absorption inhibitor per day.

Claim 111 (New): The composition according to claim 32, wherein the cardiovascular agent is an angiotensin converting enzyme (ACE) inhibitor.

Claim 112 (New): The composition according to claim 111, wherein the cardiovascular agent is captopril.

Claim 113 (New): The composition according to claim 32, wherein the cardiovascular agent is angiotensin II receptor antagonist.

Claim 114 (New): The composition according to claim 32, further comprising at least one cholesterol biosynthesis inhibitor.

Claim 115 (New): The composition according to claim 114, wherein the at least one cholesterol biosynthesis inhibitor is selected from the group consisting of lovastatin,

Expedited Procedure Under 37 C.F.C. §1.116
Examining Group 1617
Application No. 10/057,323
Paper Dated: August 29, 2007
Attorney Docket No. CV01489K (4686-045531)

pravastatin, fluvastatin, simvastatin, atorvastatin, rosuvastatin, cerivastatin and mixtures thereof.

Claim 116 (New): The composition according to claim 115, wherein the at least one cholesterol biosynthesis inhibitor is simvastatin.

Claim 117 (New): The composition according to claim 32, further comprising at least one bile acid sequestrant.

Claim 118 (New): The composition according to claim 32, further comprising nicotinic acid, niceritrol, nicofuranose or acipimox.

Claim 119 (New): The composition according to claim 32, further comprising at least one AcylCoA:Cholesterol *O*-acyltransferase Inhibitor.

Claim 120 (New): The composition according to claim 32, further comprising at least one low-density lipoprotein receptor activator.

Claim 121 (New): The composition according to claim 32, further comprising at least one Omega 3 fatty acid.

Claim 122 (New): The composition according to claim 32, further comprising at least one of plant sterols, plant stanols or fatty acid esters of plant stanols.

Claim 123 (New): The composition according to claim 32, further comprising at least one obesity control medication.

Expedited Procedure Under 37 C.F.C. §1.116
Examining Group 1617
Application No. 10/057,323
Paper Dated: August 29, 2007
Attorney Docket No. CV01489K (4686-045531)

Claim 124 (New): The composition according to claim 32, further comprising at least one blood modifier.

Claim 125 (New): The composition according to claim 32, further comprising at least one antidiabetic medication.

Claim 126 (New): A pharmaceutical composition for the treatment of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal, comprising a therapeutically effective amount of the composition of claim 32 and a pharmaceutically acceptable carrier.